Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda 1st Half Sales Rise 5.3% on New Portfolio, Weaker Yen
November 1, 2013
- MTPC Sales of Domestic Ethical Drugs Down 3.2% in April-September Period Due to Generic Competition
October 31, 2013
- DSP North America Sales Up 11.8% Due to Latuda, Japan Sales Down 4.2% in April-September Period
October 31, 2013
- Stock-Out of Mucosolate, Lemalc Due to Non-Conformance Results of Dissolution Testing, Stable Supply to Resume Next Spring: Teva Pharma Japan
October 31, 2013
- Teva Pharma Japan Notifies Customers of Stock-Out of Mucosolate L Cap.45, Lemalc Tab. 100 Due to Manufacturing Troubles
October 30, 2013
- Taiwan Approval Sought for DSP’s Antipsychotic Lurasidone
October 30, 2013
- Eli Lilly Italy Pres. Jönsson to Take Reins of Japan Operations
October 29, 2013
- Teva’s Global Medical Director Says Biosimilars Can Cut Medical Costs
October 25, 2013
- Tamiflu Supply Plan for This Season Down by 3 Million Treatment Courses against Last Season: Chugai
October 25, 2013
- Race for Top Brands for BPH Tightens as Generics Make Inroads; OAB Market Grows as Disease Entity Becomes Better Defined
October 25, 2013
- Ono Licenses Pheochromocytoma Treatment Metyrosine from Valeant
October 24, 2013
- Swiss Novartis Sees 22% Plunge in January-September Diovan Sales
October 23, 2013
- Shionogi, Nipro to Copromote Anti-Influenza Treatment Rapiacta
October 23, 2013
- Roche Still Tops in Patent Asset Ranking in Japan, Shionogi, MTPC Jumps to Second, Third Place
October 22, 2013
- Wholesalers’ Sluggish Price Settlement Rate Could Mar Reliability of Market Price Survey
October 22, 2013
- BMKK, Pfizer to Change Distribution Channel to Wholesalers for Eliquis, Remain as Copromoters
October 21, 2013
- CMIC Holdings Joins Hands with UK Firm Aesica in Contract Manufacturing Biz
October 21, 2013
- Santen Opens Office in Ho Chi Minh City
October 21, 2013
- Kissei, Kyorin Initiate PI Study of Overactive Bladder Treatment KEA-0447/KRP-EPA605
October 21, 2013
- Teva Pharma Japan to Discontinue Marketing 15% of All Products Under Selection and Concentration Strategy
October 18, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…